IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will speak at the Barclays Global Healthcare Conference in Miami, FL on March 16, 2022, at 1:35 p.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics and clinical research services for the life sciences sector, operating in over 100 countries with approximately 79,000 employees and focusing on improving healthcare outcomes through innovative solutions.
IQVIA has entered into a multi-year collaboration with argenx SE to develop new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved treatment for generalized myasthenia gravis. The undisclosed terms of the agreement will enhance clinical development, regulatory, and commercial strategies. IQVIA aims to support argenx in accelerating this process, leveraging its expertise in analytics and technology. With approximately 79,000 employees operating in over 100 countries, IQVIA continues to emphasize its role in improving healthcare outcomes.
Summary not available.
Summary not available.
IQVIA Holdings reported a strong fourth quarter with revenue of $3,636 million, up 10.2% year-over-year. GAAP net income surged by 167.2% to $318 million, translating to earnings per share of $1.63. Adjusted EBITDA reached $828 million, representing a 12.7% increase. For 2022, IQVIA reaffirmed its revenue guidance of $14.7 billion to $15 billion and raised expectations for Adjusted EBITDA and Earnings per Share. The contracted backlog in R&D Solutions grew to $24.8 billion, indicating strong future revenue potential.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 11:00 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is a global leader in analytics and clinical research services for life sciences, operating in over 100 countries with approximately 79,000 employees, focusing on improving healthcare outcomes through insights and technology.
Summary not available.
Summary not available.
IQVIA Holdings Inc. (NYSE: IQV) will release its fourth-quarter and full-year 2021 financial results on February 15, 2022, before the market opens. The management team will present a conference call at 9:00 a.m. Eastern Time on the same day. Interested participants can register in advance via the Investor Relations website. A replay of the event will be available two hours post conclusion. IQVIA is a leader in analytics and clinical research, supporting healthcare improvements across its operations in over 100 countries.
IQVIA has appointed Sheila A. Stamps to its board of directors, effective immediately. With over 40 years of experience in strategic governance and operational management, Ms. Stamps has held leadership roles in both public and private sectors, including as a senior investment advisor for the New York State Comptroller. She serves on boards of multiple public companies and has a strong background in audit and finance. Following her appointment, IQVIA's board comprises 11 directors, ten of whom are independent.